|Bid||1,381.00 x 16300|
|Ask||1,383.00 x 34600|
|Day's range||1,383.00 - 1,419.00|
|52-week range||1,339.50 - 2,703.00|
|PE ratio (TTM)||20.91|
|Dividend & yield||0.44 (2.38%)|
|1y target est||N/A|
Hikma shares were active in London trading Monday after the drugmaker unveiled a reorganization of its U.S. business that includes a change in leadership.
The FTSE 100 was up nearly 0.5 percent on the day, bringing it into positive territory for the week after its performance was dented by worries over turmoil in U.S. President Donald Trump's administration that sent stocks tumbling across the globe. Investors looked through the political uncertainty to a better earnings season and improved UK retail sales data which pointed to a brighter outlook for consumer-facing stocks.
Hikma Pharmaceuticals Plc lowered its full-year revenue forecast on Friday to reflect a delay in the launch of its generic asthma drug amid pricing pressures in the United States, sending its shares down to a three-year low. Earlier this month, the drugmaker said U.S. regulators decided not to approve its generic version of GlaxoSmithKline Plc's blockbuster lung drug Advair, citing "major" issues with the application. The company, which makes and markets branded and non-branded generic and injectable drugs, now expects full-year revenue to be in the range of $2 billion-$2.1 billion at constant currency, down from its earlier forecast of $2.2 billion.